

Brandes Investment Partners

Global Small-Mid Cap Equity Strategy Notes

Fourth Quarter 2025 (October 1 – December 31, 2025)

The Brandes Global Small-Mid Cap Equity Strategy rose 2.26% net of fees and 2.38% gross of fees, performing roughly in line with its benchmark, the MSCI ACWI SMID Cap Index, which increased 2.08%.

Annualized total return as of December 31, 2025	1-year	5-year	10-year
Brandes Global Small-Mid Cap Equity Composite (net)	32.08%	16.81%	11.38%
Brandes Global Small-Mid Cap Equity Composite (gross)	32.83%	17.54%	12.20%
MSCI ACWI SMID Cap Index	19.29%	7.27%	9.19%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

Positive Contributors

Notable contributors included holdings domiciled in the United States, as well as those in the industrials, health care and consumer discretionary sectors.

In the health care sector, Pediatrix Medical Group performed well after delivering better-than-expected quarterly results. Industrial companies Kennametal and Healthcare Services Group, as well as energy equipment company Innovex International produced solid results. Switzerland-based Swatch Group advanced as U.S. tariffs on goods from Switzerland were reduced.

Financial holdings Erste Group in Austria and OneMain in the U.S. both continued to benefit from an attractive interest rate and credit environment.

Performance Detractors

Detractors were in technology, specifically communications equipment companies Netgear and F5, as well as electronic equipment company IPG Photonics. Netgear's decline was primarily due to concerns over supply chain issues, rising memory costs, and a mixed outlook from management during their third quarter earnings call.

Consumer staples were also a detractor, specifically Edgewell Personal Care and U.K.-based Premier Foods. Edgewell declined after announcing revenue and earnings guidance below expectations.

Other detractors included pharmaceutical ingredient company Organon and communication services companies Interpublic and Spain-based Atresmedia.

Select Activity

In November, the strategy's long-held position in Premier Inc. was acquired by private equity firm Patient Square Capital for \$28.25 per share. We added Premier—one of the largest group purchasing organizations (GPOs) in the U.S. healthcare sector—to client portfolios in 2020. Before its initial public offering in 2013, Premier was owned by its healthcare provider members. Over time, those members gradually converted their ownership into publicly traded shares and reduced their stakes in the company. This process culminated in 2020, when Premier converted all remaining member-owned shares into a single publicly traded share class.

On our initial investment, the committee viewed Premier as a low-growth business with a strong balance sheet and a stable, recurring revenue model. However, several factors clouded the company's long-term outlook. These included the ongoing divestment by client members, rising customer concentration as healthcare industry consolidation accelerated, and an uncertain operating environment for healthcare providers after the pandemic. As a result, the investment committee took only a relatively small initial position.

In the following years, Premier undertook a restructuring that included selling off non-core and unrelated businesses. During this period, revenue also contracted as pandemic-era sales of personal protective equipment (PPE) normalized. The share price drifted lower as restructuring efforts extended and revenue only recovered modestly. In 2024, the investment committee increased our allocation to Premier and continued to average down the position. By late 2024 and into early 2025, conditions appeared to stabilize. Premier had sold most of its non-core assets; resumed returning capital to shareholders through dividends and share repurchases, and its core GPO business stabilized. Additionally, a healthcare-focused software offering showed promising growth potential, and the company's share price began to recover. When Patient Square Capital tendered its acquisition bid for Premier, the investment committee viewed the price as fair and voted in favor of the transaction.

A recent addition to the portfolios, NICE Ltd. is an Israel-based Contact Center-as-a-Service (CCaaS) provider. NICE maintains dual headquarters in Israel and the United States, with a customer base that is predominantly in the U.S. NICE has evolved alongside changing technology and customer requirements. Historically, the company provided software and services to help enterprises manage on-premise customer contact centers. In this role, NICE was one of several software and hardware vendors offering tools to staff, manage, measure and evaluate call center operations. The company was particularly strong in workforce engagement management (WEM) software, a critical component for effective contact center operations.

In recent years, CCaaS offerings have been increasingly adopted because they lower total cost of ownership, better integrate customer service channels and leverage automation, including AI. All of this enables a superior customer experience that can be applied to other areas of a business. NICE responded to this shift by acquiring a leading CCaaS provider, inContact, in 2016. This acquisition gave NICE a nearly complete CCaaS solution, and as cloud-based offerings grew at the expense of on-premise systems, NICE benefited from higher revenue per licensed seat. The market rewarded this industry-leading position with strong valuation multiples.

However, in 2025 rapid advances in AI capability and adoption began to cloud NICE's outlook. On one hand, improving AI functionality has accelerated the shift toward CCaaS solutions and away from on-premise deployments. On the other, the pace of change has intensified competition among CCaaS providers and has driven increased investment to incorporate advanced AI features. NICE has indicated that this heightened investment, including the approximately \$1-billion acquisition of Cognigy, will put pressure on its earnings over the next year. This uncertainty contributed to a sharp correction in the share price, pushing it to multi-year lows and compressing valuation multiples to near all-time lows.

While it is impossible to predict definitive winners and losers in the AI arms race, NICE remains favorably positioned as an established incumbent in the CCaaS market with a well-capitalized balance sheet. AI-enhanced contact center functionality could meaningfully expand the overall market size over time. We will continue to monitor the competitive landscape for evidence of NICE's performance in navigating this transition. For the patient, long-term investor, the current opportunity in NICE appears attractive.

Year-to-Date Briefing

The Brandes Global Small-Mid Cap Value Equity Strategy climbed 32.08% net of fees and 32.83% gross of fees, outperforming its benchmark, the MSCI ACWI SMID Cap Index, which was up 19.29% for the year ended December 31, 2025.

Stock selection across multiple sectors drove our outperformance relative to the benchmark. Leading contributors included investments in financials, led by Greece-based Piraeus Financial, Austria-based Erste Group Bank and Spain-based CaixaBank. The strategy also gained from its industrials, led by Brazil-based regional jet manufacturer Embraer, and from health care, led by U.S.-based Elanco Animal Health. Consumer staples firm Netherlands-based JDE Peet's has also seen its stock rise materially in anticipation of its potential acquisition by Keurig Dr Pepper.

The most significant detractors by sector was our overweight to consumer staples and health care as both lagged the overall benchmark; however, our holdings in aggregate performed significantly better than those in the index. Company detractors were multinational consumer products company Edgewell Personal Care and health care firms Dentsply Sirona

and Organon. Other detractors included technology hardware company Netgear and consumer products company France-based Societe BIC.

Current Positioning

The strategy holds key overweight positions versus the benchmark in the consumer staples, communication services and health care sectors. Meanwhile, we are underweight in typically cyclical business categories, such as financials, materials and industrials. We also own comparatively fewer perceived “safe havens,” such as utilities.

Geographically, we continue to find value opportunities outside the United States, especially in the United Kingdom. The portfolio is materially underweight versus the benchmark in its allocation to the United States, although our weight did increase during the year and the benchmark allocation declined as international stocks outperformed the U.S. by the largest margin in 30 years (MSCI EAFE vs. MSCI USA).

Global small-mid cap equities continue to represent, in our opinion, fertile ground for fundamentally solid businesses trading at a discount to their estimated intrinsic values. Within the asset class, value stocks (MSCI World SMID Cap Value) continue to trade in the highest quartile of discount levels compared to the broader market (MSCI World SMID Cap) on a variety of valuation metrics, including forward price/earnings, price/cash flows, and enterprise value/sales.

We believe that paying extremely close attention to valuations enables us to choose opportunities that others may miss. From our perspective, selectivity and a laser focus on margin of safety remain paramount in any and all market environments. We are enthusiastic about the potentially undervalued companies we are finding and the diversification offered by the Brandes Global Small-Mid Cap Equity Strategy.

For term definitions, please refer to <https://www.brandes.com/termdefinitions>.

For index definitions, please refer to <https://www.brandes.com/benchmark-definitions>.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

United States: Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

Singapore/Asia: FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for “institutional investors” or “accredited investors” as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

Canada: FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.